CONTEXT: The epithelial marker E-cadherin plays a crucial role in epithelial-mesenchymal transition (EMT). Decreased protein content in somatotroph adenomas has been associated with increased tumor size, invasion, and poor response to somatostatin analog (SA) treatment, but the potential mechanisms of EMT progression in these adenomas are lacking. OBJECTIVE: We hypothesized that characterization of EMT-related transcripts in somatotroph adenomas could identify novel therapeutic targets in individuals with poor response to SA treatment and provide more knowledge of the mechanism of EMT progression. PATIENTS: Fifty-three patients with acromegaly participated in the study. RESEARCH DESIGN AND METHODS: We performed microarray analysis of 16 adenomas, eight with high expression and eight with low expression of E-cadherin, in order to identify EMT-related transcripts. Candidate transcripts were further explored in vivo in 53 adenomas and in vitro in a rat pituitary GH-producing cell (GH3) after exploring three models for reducing E-cadherin and inducing a mesenchymal phenotype. RESULTS: In vivo E-cadherin mRNA expression in tumor tissue is associated negatively with tumor size and invasiveness and positively with GH and IGF-I levels in serum and response to SA treatment. Microarray and subsequent PCR analysis identify several EMT-related genes associated with E-cadherin expression. In vitro, few of these EMT-related genes were regulated by silencing E-cadherin or by TGF-β1 treatment in GH3 cells. In contrast, silencing Esrp1 in GH3 cells regulated many of the EMT-related transcripts. CONCLUSION: These results indicate that ESRP1 could be a master regulator of the EMT process in pituitary adenomas causing acromegaly.
CONTEXT: The epithelial marker E-cadherin plays a crucial role in epithelial-mesenchymal transition (EMT). Decreased protein content in somatotroph adenomas has been associated with increased tumor size, invasion, and poor response to somatostatin analog (SA) treatment, but the potential mechanisms of EMT progression in these adenomas are lacking. OBJECTIVE: We hypothesized that characterization of EMT-related transcripts in somatotroph adenomas could identify novel therapeutic targets in individuals with poor response to SA treatment and provide more knowledge of the mechanism of EMT progression. PATIENTS: Fifty-three patients with acromegaly participated in the study. RESEARCH DESIGN AND METHODS: We performed microarray analysis of 16 adenomas, eight with high expression and eight with low expression of E-cadherin, in order to identify EMT-related transcripts. Candidate transcripts were further explored in vivo in 53 adenomas and in vitro in a rat pituitary GH-producing cell (GH3) after exploring three models for reducing E-cadherin and inducing a mesenchymal phenotype. RESULTS: In vivo E-cadherin mRNA expression in tumor tissue is associated negatively with tumor size and invasiveness and positively with GH and IGF-I levels in serum and response to SA treatment. Microarray and subsequent PCR analysis identify several EMT-related genes associated with E-cadherin expression. In vitro, few of these EMT-related genes were regulated by silencing E-cadherin or by TGF-β1 treatment in GH3 cells. In contrast, silencing Esrp1 in GH3 cells regulated many of the EMT-related transcripts. CONCLUSION: These results indicate that ESRP1 could be a master regulator of the EMT process in pituitary adenomas causing acromegaly.
Authors: Katja Kiseljak-Vassiliades; Nichole E Carlson; Manuel T Borges; B K Kleinschmidt-DeMasters; Kevin O Lillehei; Janice M Kerr; Margaret E Wierman Journal: Endocrine Date: 2014-08-17 Impact factor: 3.633
Authors: Katja Kiseljak-Vassiliades; Taylor S Mills; Yu Zhang; Mei Xu; Kevin O Lillehei; B K Kleinschmidt-DeMasters; Margaret E Wierman Journal: Endocrinology Date: 2017-05-01 Impact factor: 4.736